logo

KAPA

Kairos Pharma·AMEX
--
--(--)
--
--(--)
3.76 / 10
Netural

KAPA's fundamental profile is mixed: interest-coverage ratio (15.48%) and revenue growth (78.47% YoY) are positives, but Days Sales Outstanding (72.55) and negative Revenue-MV (-0.26) flag working-capital and valuation concerns. Net income-to-revenue (-0.17) further tempers enthusiasm, suggesting a defensive approach is warranted.

Fundamental(3.76)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight20.47%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.75%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.25%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight16.32%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight16.34%
1M Return8.45%
PB-ROE
Value0.94
Score2/3
Weight20.35%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.63%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.67%
1M Return0.43%
Asset-MV
Value-0.50
Score1/3
Weight11.94%
1M Return6.68%
Cash-MV
Value-0.07
Score2/3
Weight16.04%
1M Return8.41%
Is KAPA undervalued or overvalued?
  • KAPA scores 3.76/10 on fundamentals and holds a Fair valuation at present. Backed by its -65.63% ROE, 0.00% net margin, -2.72 P/E ratio, 1.67 P/B ratio, and -24.00% earnings growth, these metrics solidify its Netural investment rating.